Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...

Pfizer (PFE), and Sanofi (SNY) drew increased attention on Tuesday as traders reacted to the U.S. government’s move to halt ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Pfizer and BioNTech generated more than $3.3 billion in revenue from global sales of their vaccine Comirnaty last year, while Moderna generated $3.2 billion from its vaccine Spikevax, according to ...

A 2022 study reported that the Pfizer and Moderna vaccines led to an additional 22 and 31 myocarditis cases, respectively, for every million 18- to 29-year-olds in the U.S.

Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...

Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday.

Moderna and Pfizer are both competing for federal contracts with HHS to contribute to an mRNA vaccine stockpile in case the H5N1 virus spreads to humans.

Moderna sued them in 2022 for allegedly copying its messenger RNA technology. Pfizer and BioNTech, its German business partner, filed a countersuit, alleging that Moderna’s patent was invalid.